News in Brief: Head-to-head trial of BTKi in CLL at ASCO; EBV-positive lymphoma with MTX; Undiagnosed haemochromatosis in Australia

Head-to-head trial of BTKi in CLL: ASCO First results of a head-to-head trial of acalabrutinib (Aca) versus ibrutinib (Ib) in previously treated chronic lymphocytic leukaemia show Aca had non inferior PFS, less cardiotoxicity and fewer discontinuations due to adverse events. The findings were presented this week at ASCOs annual scientific meeting and mark the first ...

Already a member?

Login to keep reading.

© 2022 the limbic